Here’s Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company

2 days ago 5

Soumya Eswaran

Thu, May 14, 2026 astatine 9:12 AM CDT 4 min read

Aristotle Capital Management, LLC, an concern absorption company, released its “Core Equity Fund” first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. During the archetypal quarter, the U.S. equity marketplace declined, with the S&P 500 Index falling by 4.33%. The fixed-income assemblage besides saw a downturn; the Bloomberg U.S. Aggregate Bond Index fell by 0.05%. In the quarter, the Fund (Class I-2) posted a full instrumentality of -4.45%, compared to the S&P 500 Index’s -4.33% return. The Fund’s underperformance successful the 4th was driven by the allocation effect, portion information enactment contributed positively. In this environment, the Fund continues to absorption connected companies experiencing secular tailwinds oregon robust product-driven cycles. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Aristotle Core Equity Fund highlighted Tempus AI, Inc. (NASDAQ:TEM) arsenic a caller addition. Tempus AI, Inc. (NASDAQ:TEM) is simply a healthcare exertion institution that focuses connected delivering precision medicine solutions done the usage of AI and genomic data. On May 13, 2026, Tempus AI, Inc. (NASDAQ:TEM) closed astatine $45.90 per share. One-month instrumentality of Tempus AI, Inc. (NASDAQ:TEM) was -14.86%, and its shares mislaid 25.98% implicit the past 52 weeks. Tempus AI, Inc. (NASDAQ:TEM) has a marketplace capitalization of $8.31 billion.

Aristotle Core Equity Fund stated the pursuing regarding Tempus AI, Inc. (NASDAQ:TEM) successful its Q1 2026 capitalist letter:

"Tempus AI, Inc. (NASDAQ:TEM) is simply a healthcare exertion institution specializing successful AI-enabled precision medicine solutions. By leveraging AI and instrumentality learning, Tempus connects laboratory trial results with objective information to amended diligent attraction crossed aggregate diseases. The institution operates done 3 main concern units: Genomics (Diagnostics), which offers precocious familial investigating and diagnostics; Data and Services, which commercializes de-identified healthcare information and supports objective trials; and AI Applications, which develops algorithmic diagnostics and objective determination enactment tools. Tempus collaborates with starring pharmaceutical and biotechnology firms, positioning itself arsenic a cardinal innovator successful some oncology and broader healthcare markets.

In our opinion, Tempus stands retired arsenic a compelling concern accidental owed to its alignment with cardinal secular trends specified arsenic AI, Data Analysis and Monetization, and Personalized Medicine. Since going nationalist successful mid-2024, Tempus has demonstrated awesome growth, driven by some integrated enlargement and strategical acquisitions similar Ambry. The company’s robust portfolio successful genomics and diagnostics—spanning oncology, hereditary hazard appraisal and precocious testing—along with its rapidly increasing information and applications segment, positions Tempus astatine the forefront of personalized medicine. The company’s expanding database of implicit 45 cardinal diligent records enhances its worth proposition to probe partners, and ongoing innovations are expected to thrust some gross and mean selling terms growth, making Tempus well-situated to capitalize connected the evolving healthcare landscape."

Read Entire Article